PARP inhibitor re-treatment: the future of maintenance therapy for relapsed ovarian cancer?

Gynae_PP_ Eric Pujade-Lauraine

Live discussion during the Proffered Paper session - Gynaecological cancers at the ESMO Congress 2021

A significant progression-free survival improvement after re-treatment with olaparib was reported in the OReO/ENGOT Ov-38 trial

Late-Breaking results from the phase III OReO/ENGOT Ov-38 trial (LBA33) demonstrated that re-treatment with olaparib significantly prolonged progression-free survival (PFS) compared with placebo in both BRCA1/2-mutated (4.3 months versus 2.8 months, respectively, hazard ratio [HR] 0.57; p=0.022) and non-BRCA1/2-mutated disease (5.3 months versus 2.8 months, respectively, HR 0.43; p=0.002).

More and more patients with epithelial ovarian cancer will receive a PARP inhibitor as upfront therapy following positive results in the SOLO1, PAOLA-1 and the PRIMA/ENGOT-OV26/GOG-3012 studies in which olaparib prolonged the time to recurrence in BRCA1/2-mutated disease and niraparib prolonged progression-free survival time, regardless of homologous-recombination status. However, conserving platinum sensitivity in patients with disease progression on or after PARP inhibitor maintenance remains an unresolved issue. OReO/ENGOT Ov-38 is the first phase III study to evaluate PARP inhibitor maintenance re-treatment in this setting, and the findings will undoubtedly help inform the most appropriate strategy.

In the OReO/ENGOT Ov-38 study, patients with platinum-sensitive, non-mucinous epithelial ovarian cancer and one prior line of PARP inhibitor maintenance therapy who were responsive to their most recent platinum-based chemotherapy were randomised 2:1 to olaparib (300 mg bid [or 250 mg bid if 300 mg not previously tolerated]) or placebo until disease progression. Of 220 patients enrolled, 112 had BRCA1/2-mutated disease and 108 had non-BRCA1/2-mutated disease. Patients were heavily pre-treated, with most patients in both the BRCA1/2-mutated (93%) and non-BRCA1/2-mutated (86%) arms having received ≥3 prior lines of chemotherapy. The median duration of prior PARP inhibitor therapy was longer for patients with BRCA1/2-mutated disease (18.3–21.2 months) than those with non-BRCA1/2-mutated disease (12.4–12.6 months).

Among patients with BRCA1/2-mutated ovarian cancer, 6-month PFS rates were 35% with olaparib and 13% with placebo, while at 12 months, the respective rates were 19% and 0%. In the non-BRCA1/2-mutated cohort, respective PFS rates with olaparib and placebo were 30% and 7% at 6 months, and 14% and 0% at 12 months.

LBA33_ESMO 2021

Figure. Significant PFS benefit following rechallenge with maintenance olaparib in patients with heavily pre-treated BRCA1/2-mutated ovarian cancer (Abstract LBA33, ESMO 2021)

Adverse events (AEs) were more common with olaparib than placebo. Among patients with BRCA1/2-mutated disease, grade ≥3 AEs occurred in 15% of olaparib-treated versus 5% of placebo-treated patients, while among non-BRCA1/2-mutated patients, these AEs occurred in 21% of olaparib-treated versus 8% of placebo-treated patients. Treatment discontinuation because of an AE also occurred more frequently in olaparib-treated patients (3% with BRCA1/2-mutated disease and 1% with non-BRCA1/2-mutated disease) than in placebo-treated patients (0% of patients). 

Pujade-Lauraine E. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial. ESMO Congress 2021, Abstract LBA33 

Proffered Paper session – Gynaecological cancers 17.9.2021, h. 14:20 – 14:30, Channel 3

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.